JP2008520707A5 - - Google Patents

Download PDF

Info

Publication number
JP2008520707A5
JP2008520707A5 JP2007543288A JP2007543288A JP2008520707A5 JP 2008520707 A5 JP2008520707 A5 JP 2008520707A5 JP 2007543288 A JP2007543288 A JP 2007543288A JP 2007543288 A JP2007543288 A JP 2007543288A JP 2008520707 A5 JP2008520707 A5 JP 2008520707A5
Authority
JP
Japan
Prior art keywords
dose
predetermined
surgically created
size
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/041884 external-priority patent/WO2006073586A2/en
Publication of JP2008520707A publication Critical patent/JP2008520707A/ja
Publication of JP2008520707A5 publication Critical patent/JP2008520707A5/ja
Pending legal-status Critical Current

Links

JP2007543288A 2004-11-17 2005-11-17 放射線量測定法及び遮断抗体並びに癌を治療する際の該方法及び使用 Pending JP2008520707A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62874004P 2004-11-17 2004-11-17
PCT/US2005/041884 WO2006073586A2 (en) 2004-11-17 2005-11-17 Radiation dosimetry and blocking antibodies and methods and uses threfor in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2008520707A JP2008520707A (ja) 2008-06-19
JP2008520707A5 true JP2008520707A5 (https=) 2008-12-18

Family

ID=36647943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543288A Pending JP2008520707A (ja) 2004-11-17 2005-11-17 放射線量測定法及び遮断抗体並びに癌を治療する際の該方法及び使用

Country Status (8)

Country Link
US (1) US20060127311A1 (https=)
EP (1) EP1817062A4 (https=)
JP (1) JP2008520707A (https=)
AU (1) AU2005323377A1 (https=)
CA (1) CA2587172A1 (https=)
RU (1) RU2007121808A (https=)
WO (1) WO2006073586A2 (https=)
ZA (1) ZA200704642B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119493A1 (en) * 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
CN114404429B (zh) * 2021-11-30 2023-06-30 重庆医科大学附属第二医院 一种纳米银修饰的单宁酸-铁网络的载药纳米复合物及其制备方法和逆转肿瘤耐药应用
CN120813388A (zh) * 2023-03-02 2025-10-17 日本医事物理股份有限公司 放射性金属标记抗体、放射性药物及化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
USRE38008E1 (en) * 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US6787153B1 (en) * 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
AU6445894A (en) * 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US6022521A (en) * 1995-05-04 2000-02-08 The Regents Of The University Of Michigan Method of establishing the optimal radiation dose for radiopharmaceutical treatment of disease
WO1999036105A2 (en) * 1998-01-16 1999-07-22 Mca Development B.V. USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE
NZ508674A (en) * 1998-06-04 2003-09-26 Univ Michigan A method for determining patient-specific dosimetry of a radippharmaceutical
US7067109B1 (en) * 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US20020187100A1 (en) * 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
US6455026B1 (en) * 2001-03-23 2002-09-24 Agy Therapeutics, Inc. Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
US7011814B2 (en) * 2001-04-23 2006-03-14 Sicel Technologies, Inc. Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject

Similar Documents

Publication Publication Date Title
Avril et al. Monitoring response to treatment in patients utilizing PET
Green et al. High resolution PET, SPECT and projection imaging in small animals
Hasegawa et al. Dual-modality imaging of function and physiology
Knox et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer
Wagner et al. Approaches using molecular imaging technology—use of PET in clinical microdose studies
ES2802234T3 (es) Sistemas y métodos para determinar la dosis óptima y específica para el paciente de anticuerpos dirigidos al tumor
JP2003502433A5 (https=)
RU2019142507A (ru) Композиции, способы и системы для синтеза и применение визуализирующих средств
Pfeifer et al. Effect of Ritonavir on 99mTechnetium–Mebrofenin Disposition in Humans: A Semi‐PBPK Modeling and In Vitro Approach to Predict Transporter‐Mediated DDIs
CN103890611A (zh) 数据驱动的对事件接受/拒绝逻辑的优化
Chefer et al. Modeling [18F]-FDG lymphoid tissue kinetics to characterize nonhuman primate immune response to Middle East respiratory syndrome-coronavirus aerosol challenge
Dunphy et al. First-in-human trial of epichaperome-targeted PET in patients with cancer
Okamura et al. Imaging of activity of multidrug resistance–associated protein 1 in the lungs
Ryeom et al. Biliary atresia: feasibility of mangafodipir trisodium–enhanced MR cholangiography for evaluation
Schoffelen et al. Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method
Zacherl et al. Molecular imaging of cardiac CXCR4 expression in a mouse model of acute myocardial infarction using a novel 68Ga-mCXCL12 PET tracer
Deloar et al. Internal absorbed dose estimation by a TLD method for-FDG and comparison with the dose estimates from whole body PET
JP2008520707A5 (https=)
Forrer et al. From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo 99mTc-DMSA-SPECT and molecular imaging
JP5457191B2 (ja) 被検体内の放射性医薬品の分布を決定するシステム、方法及びコンピュータプログラム
Mahmoudi et al. Patient-specific dosimetry in radioligand therapy (RLT) for metastatic prostate cancer using 177Lu-DKFZ-PSMA-617
Aktolun et al. Nuclear oncology
Plyku et al. Strengths and weaknesses of a planar whole-body method of 153Sm dosimetry for patients with metastatic osteosarcoma and comparison with three-dimensional dosimetry
US20250049972A1 (en) METHOD OF DETECTING PROSTATE CANCER IN A HUMAN SUBJECT USING A Cu 64 PSMA I&T INJECTION
Wang et al. The specificity and accuracy of 111In-hexavalent lactoside in estimating liver reserve and its threshold value for mortality in mice